Biomedical Engineering Reference
In-Depth Information
M
ENG
A, J
ESSEN
JR, and L
IN
S (1999). Transgenesis. Methods Cell Biol 60: 133-148.
M
ILLER
DS, G
RAEFF
C, D
ROULLE
L, F
RICKER
S, and F
RICKER
G (2002). Xenobiotic efflux pumps in isolated fish
brain capillaries. Am J Physiol Regul Integr Comp Physiol 282(1): R191-198.
M
ULLER
C, B
AILLY
JD, G
OUBIN
F, L
AREDO
J, J
AFFREZOU
JP, B
ORDIER
C, and L
AURENT
G (1994). Verapamil
decreases P-glycoprotein expression inmultidrug-resistant human leukemic cell lines. Int J Cancer 56(5):
749-754.
P
OTSCHKA
H and L
OSCHER
W (2001). In vivo evidence for P-glycoprotein-mediated transport of phenytoin at
the blood-brain barrier of rats. Epilepsia 42: 1366-1368.
R
AUTIO
J, H
UMPHREYS
JE, W
EBSTER
LO, B
ALAKRISHNAN
A, K
EOGH
JP, K
UNTA
JR, S
ERABJIT
-S
INGH
CJ, and P
OLLI
JW (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential
of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34(5): 786-792.
R
OSE
JM, P
ECKHAM
SL, S
CISM
JL, and A
UDUS
KL (1998). Evaluation of the role of P-glycoprotein
in ivermectin uptake by primary cultures of bovine brain microvessel endothelial cells. Neurochem
Res 23(2): 203-209.
S
ADLER
KC, A
MSTERDAM
A, S
OROKA
C, B
OYER
J, and H
OPKINS
N (2005). A genetic screen in zebrafish
identifies the mutants vps18, nf2 and foie gras as models of liver disease. Development 132(15):
3561-3572.
S
CHINKEL
AH (1999). P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv DrugDeliv Rev 36(2-3):
179-194.
S
CHINKEL
AH, S
MIT
JJ,
VAN
T
ELLINGEN
O, B
EIJNEN
JH, W
AGENAAR
E,
VAN
D
EEMTER
L, M
OL
CA,
VAN DER
V
ALK
MA, R
OBANUS
-M
AANDAG
EC,
TE
R
IELE
HP, et al. (1994). Disruption of the mouse mdr1a
P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to
drugs. Cell 77(4): 491-502.
S
CHINKEL
AH, W
AGENAAR
E, M
OL
CA, and
VAN
D
EEMTER
L (1996). P-glycoprotein in the blood-brain barrier
of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97(11):
2517-2524.
S
TEWART
PA, B
ELIVEAU
R, and R
OGERS
KA (1996). Cellular localization of P-glycoprotein in brain versus
gonadal capillaries. J Histochem Cytochem 44(7): 679-685.
T
SUJI
A, T
ERASAKI
T, T
AKABATAKE
Y, T
ENDA
Y, T
AMAI
I, Y
AMASHIMA
T, M
ORITANI
S, T
SURUO
T, and Y
AMASHITA
J
(1992). P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial
cells. Life Sci 51(18): 1427-1437.
VAN
A
SPEREN
J, S
CHINKEL
AH, B
EIJNEN
JH, N
OOIJEN
WJ, B
ORST
P, and
VAN
T
ELLINGEN
O (1996). Altered
pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst 88(14):
994-999.
W
ANDEL
C, K
IM
R, W
OOD
M, and W
OOD
A (2002). Interaction of morphine, fentanyl, sufentanil, alfentanil,
and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96(4): 913-920.
W
ANG
Q, Y
ANG
H, M
ILLER
DW, and E
LMQUIST
WF (1995). Effect of the p-glycoprotein inhibitor, cyclosporin
A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats.
Biochem Biophys Res Commun 211(3): 719-726.
W
EISS
J, K
ERPEN
CJ, L
INDENMAIER
H, D
ORMANN
SM, and H
AEFELI
WE (2003). Interaction of antiepileptic
drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 307(1): 262-267.
W
ESTERFIELD
M (1993). The Zebrafish Book: a guide for the laboratory use of zebrafish. The University of
Oregon Press.
W
ULLIMANN
MF and R
EICHERT
H (1996). Neuroanatomy of the zebrafish brain. Birkhauser, Basel, 144 pp.
X
IA
CQ, M
ILTON
MN, and G
AN
LS (2007). Evaluation of drug-transporter interactions using in vitro and in
vivo models. Curr Drug Metab 8(4): 341-363.
Y
UMOTO
R, M
URAKAMI
T, N
AKAMOTO
Y, H
ASEGAWA
R, N
AGAI
J, and T
AKANO
M(1999). Transport of rhodamine
123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of
cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289(1): 149-155.
Search WWH ::
Custom Search